Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.
Kfir-Erenfeld S, Asherie N, Lebel E, Vainstein V, Assayag M, Dubnikov Sharon T, Grisariu S, Avni B, Elias S, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Zelmanovich V, Zimran E, Pick M, Roziner I, Kenett RS, Cohen YC, Avivi I, Cohen CJ, Gatt MEE, Stepensky P.
Kfir-Erenfeld S, et al. Among authors: avni b.
Blood Adv. 2024 May 20:bloodadvances.2024012967. doi: 10.1182/bloodadvances.2024012967. Online ahead of print.
Blood Adv. 2024.
PMID: 38768428